EPAS1 and metabolic dysfunction-associated steatotic liver disease: In other words, a therapeutic strategy designed to directly inhibit liver HIF-2α might not be suitable as a therapy for NAFLD, resulting in an increased risk to elevate hepatic glucose production and thus aggravate type 2 diabetes [42].